肝病研究所

上海中医药大学、上海市中医药研究院肝病研究所是以中医药防治慢性肝脏疾病为主要研究方向，集科研、医疗、教学为一体的研究机构。其前身为上海中医学院晚期血吸虫病研究小组，由我国著名老中医、原上海中医学院院长王玉润教授在上世纪70年代创办，于1996年经上海市卫生局批准成立。经过近30年的建设，已成长为中西医相结合、临床与基础相结合，医教研协调发展，在肝纤维化肝硬化研究领域具有特色优势及一定国际影响力的研究机构。首任所长刘平教授，第二任所长徐列明教授，第三任所长刘成海教授，现任所长冯琴教授。

【主要研究方向与发展目标】

研究所自上世纪90年代成立以来，坚持以慢性乙型肝炎肝纤维化肝硬化、酒精性和非酒精性脂肪性肝病等常见肝病的中医药防治基础为主攻方向，以中医药的继承与创新为指导思想，以提高临床疗效为目标，以中医药现代化、国际化为己任，在肝纤维化研究方向保持国内领先，并形成一定国际学术影响力，是具备临床与基础紧密结合的良好技术平台的国内一流研究机构。

【研究基地与平台】

肝病研究所是我国中医医疗机构中唯一连续承担国家“六·五”至“十二·五” 有关病毒性肝炎肝纤维化的科技攻关和重大专项的单位。现为国家教育部重点学科（中医内科学）及肝肾疾病病证教育部重点实验室的核心团队、为国家中医药管理局重点学科(中医肝胆病学)、中医肝病重点研究室及首批三级实验室(细胞生物学实验室)；为上海市重点优势学科、上海市中医临床重点实验室等，是中国中西医结合肝病专业委员会挂靠单位。

研究所拥有良好的实验室平台，实验室用地 1000平方米，拥有Maldi-Tof 质谱仪、蛋白组学成象系统、芯片分析仪、高内涵药物筛选系统荧光活体内镜、UPLC-MS 液质联用仪、液体闪烁发光测定仪、数字病理系统、激光共聚焦显微镜、双向电泳仪等先进仪器设备，总价值3000余万元。设备良好，并实现对外开放。

【研究团队】

肝病研究所为全国首批中医内科博士点和博士后流动站之一。人才培养分为博士后、博士、硕士、七年制本硕连读、五年制本科生、进修生等层次和梯队。

研究所拥有一支精干的科研与临床队伍，目前共有人员16位，正高7名，副高3名，另聘兼职人员4名。其中，博导7名，硕导6名。团队有中国中西医结合肝病专业委员会名誉主委、主委1人，国家杰出青年基金获得者1人，教育部优秀新世纪人才1人，卫生部有突出贡献中青年专家2人，上海市名中医3人，上海市领军人才3人，上海市曙光学者2人，上海市优秀学科带头人3人，享受国务院特殊津贴专家3名等。

【主要学术成绩】

二十多年来，研究所承担并完成国家十一五、十二五、十三五科技重大专项7 项，国家自然基金重点项目4项，国家自然基金面上及青年项目60余项。截止到2025年，获得国家及省部级二等奖以上奖励共计26项，发表论文1549篇，其中SCI 期刊源343篇。获专利授权34项，成果转化6项。

研究所历经三代人的努力，创立肝纤维化“正虚血瘀”中医病机理论，成功研制出国家抗肝纤维化中药新药— “扶正化瘀胶囊”，该产品目前已经广泛用于我国与东南亚地区，相关成果获得国家科技进步二等奖。开展并完成扶正化瘀片抗难治性慢性丙型肝炎肝纤维化美国II期临床试验，引领了我国中医药抗肝纤维化的研究发展方向，并促进其国际化发展。

立足临床实践及既往研究，提出肝硬化虚损生积病机理论假说，通过临床观察、以效证因的中医研究方式，揭示了基于疗效的肝硬化虚损生积的病理机制，建立“益气化瘀”治疗肝硬化的基本治法，解析其主要效应物质基础，并阐明辨证论治、方证对应的现代病理生物学基础。相关结果获上海市科技进步一等奖、中国中西医结合学会科技进步一等奖。

【未来发展方向】

研究所将继续坚持走面向临床、面向市场、面向国际的转型之路，将进一步优化机制、整合资源，促进优秀青年人才脱颖而出，促进科技成果的竞相迸放。将以高标准、严要求，加倍努力推动研究所的建设和发展，建成中医临床特色鲜明、学术研究水平领先、转化应用成绩显著的研究机构。

【联系方式】

地址：上海市浦东新区张衡路528号科教楼9楼

电话：021-20256521

E-mail: gbyjstcm@shutcm.edu.cn

Institute of Liver Diseases

The Shanghai University of Traditional Chinese Medicine's Institute of Liver Diseases, established in 1996 and evolving from a schistosomiasis research group founded in the 1970s by Professor Wang Yurun, integrates research, clinical practice, and teaching in traditional Chinese medicine (TCM) for chronic liver diseases. After nearly 30 years of development, it has become a leading national institution, combining TCM and Western medicine, clinical and basic research, with a focus on liver fibrosis and cirrhosis, and has gained international recognition. The institute has been led by four directors: Professors Liu Ping, Xu Leiming, Liu Chenghai, and currently, Feng Qin.

【Major Research Fields and Development Goals】

Since the 1990s, the Institute has focused on TCM-based prevention and treatment of common liver diseases, such as chronic hepatitis B, liver fibrosis, cirrhosis, and alcoholic and non-alcoholic fatty liver diseases. Guided by TCM principles, it aims to enhance clinical efficacy and promote TCM modernization and internationalization. The Institute has achieved domestic leadership in liver fibrosis research and established a strong platform for integrating clinical practice with basic research.

【Research Bases and Platforms】

The Institute of Liver Diseases is uniquely positioned as the sole TCM - based medical institution in China that has continuously undertaken national sci - tech projects on viral hepatitis liver fibrosis from the 6th to 12th Five - Year Plans. Presently, it serves as the core team for the National Education Ministry's Key Laboratory of Hepatorenal Diseases and the National Administration of Traditional Chinese Medicine's Key Discipline of TCM Hepatobiliary Medicine. Additionally, it is the TCM Liver Disease Key Laboratory and one of the first third - level laboratories (in cell biology). It is recognized as a key advantageous discipline in Shanghai and a key TCM clinical laboratory in Shanghai. The Institute is also the affiliated unit of the China Society of Integrated Traditional and Western Medicine for Liver Disease.

The Institute boasts a state - of - the - art laboratory spanning 1,000 square meters. Equipped with advanced instruments such as a MALDI - TOF mass spectrometer, protein group imaging system, chip analyzer, high - content drug screening system, fluorescent in - vivo endoscope, UPLC - MS liquid - mass spectrometer, liquid scintillation counter, digital pathology system, laser confocal microscope, and two - dimensional electrophoresis instrument, the laboratory's facilities are worth over 30 million yuan. These well - maintained facilities are accessible to external users.

【Research Team】

The Liver Disease Research Institute is one of China's first doctoral programs and postdoctoral research stations in TCM internal medicine. It nurtures talent at various levels, including postdoctoral researchers, doctoral and master's students, seven-year integrated undergraduate and master's students, five-year undergraduate students, and trainees. The institute is home to a lean and efficient team of 16 researchers and clinicians. Among them, seven hold senior research titles, three hold associate senior research titles, and four are adjunct professors. Seven serve as doctoral supervisors, and six as master's supervisors. The team boasts a former chair of the China Society of Integrated Traditional and Western Medicine for Liver Disease, a National Outstanding Youth Fund recipient,  a Ministry of Education New Century Talent Program recipient, two outstanding mid-career and young experts from the Ministry of Health, three renowned TCM practitioners in Shanghai, three Shanghai Leading Talent Program recipients, two Shanghai Dawn Scholars, three Shanghai Outstanding Discipline Leaders, and three experts enjoying a special government allowance from the State Council.

【Major Academic Achievements】

Over the past 20 years, the Institute has undertaken and completed seven major national technology projects during the 11th, 12th, and 13th Five-Year Plans, four key projects funded by the National Natural Science Foundation, and over 60 general and youth projects under the same foundation. By 2025, the institute has received a total of 26 national-level and ministerial/provincial-level awards of second-class or higher, published 1,549 research papers (including 343 in SCI-indexed journals), obtained 34 authorized patents, and achieved 6 technology transfers.

Through the efforts of three generations of researchers, the Institute has established the TCM pathogenesis theory of Zheng Xu Xue Yu for liver fibrosis. It has successfully developed a national TCM drug for anti-liver fibrosis, Fu Zheng Hua Yu Capsules, which is now widely used in China and Southeast Asia. This achievement was awarded the National Science and Technology Progress Second Prize. The Institute also conducted and completed Phase II clinical trials in the United States for Fu Zheng Hua Yu Tablets targeting refractory chronic hepatitis C liver fibrosis. This work has guided the development of TCM research on anti-liver fibrosis in China and promoted its internationalization.

Based on clinical practice and previous research, the Institute proposed the TCM pathogenesis theory hypothesis of Xu Sun Sheng Ji for liver cirrhosis. Through clinical observation and TCM research methods that validate causes through therapeutic effects, it revealed the pathological mechanism of Xu Sun Sheng Ji in liver cirrhosis. It established the basic TCM treatment method of Yi Qi Hua Yu for liver cirrhosis, clarified its main material basis, and explained the modern pathological and biological basis of TCM syndrome differentiation and treatment, as well as the correspondence between formula and syndrome. These results have received the Shanghai Science and Technology Progress First Prize and the China Society of Integrated Traditional and Western Medicine Science and Technology Progress First Prize.

【Future Development Direction】

The Institute will continue to follow a transformative path oriented toward clinical practice, market demands, and internationalization. It will further optimize mechanisms, integrate resources, and foster the emergence of outstanding young talents. By promoting the proliferation of scientific and technological achievements, the Institute will strive to advance its construction and development with high standards and strict requirements. The goal is to establish itself as a research institution with distinctive TCM clinical characteristics, leading academic research levels, and significant achievements in technology transfer and application.

【Contact Information】

Address: 9th Floor, Science and Education Building, No.528, Zhangheng Road, Pudong New Area, Shanghai

Tel: 021-20256521

E-mail: gbyjstcm@shutcm.edu.cn